Development of a leishmaniasis vaccine: the importance of MPL. (Q35192190)

7 August 2017

1 reference

title

Development of a leishmaniasis vaccine: the importance of MPL. (English)

1 reference

7 August 2017

1

Steven G Reed

1 reference

7 August 2017

2

Rhea N Coler

1 reference

7 August 2017

Antonio Campos-Neto

3

1 reference

PubMed ID

12899575

7 August 2017

language of work or name

1 reference

1 April 2003

1 reference

Expert Review of Vaccines

7 August 2017

1 reference

7 August 2017

2

1 reference

7 August 2017

239-252

1 reference

7 August 2017

2

1 reference

Visceral leishmaniasis: more prevalent and more problematic

7 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.239

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.239

Indian kala-azar caused by Leishmania tropica

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.239

Emerging Leishmania/HIV co-infection in Africa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.239

Global control and Leishmania HIV co-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.239

The immune response to Leishmania: mechanisms of parasite control and evasion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.239

The leishmaniases as model zoonoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.239

Vaccines against human parasitic diseases: an overview.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.239

Designer vaccines for parasitic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.239

Recent trends in vaccine development and immunization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.239

The regulation of immunity to Leishmania major

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.239

T-cell and cytokine responses in leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.239

Immunology of leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.239

Class II major histocompatibility complex-deficient mice initially control an infection with Leishmania major but succumb to the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.239

Course of Leishmania infection in beta 2-microglobulin-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.239

Cytokines in the differentiation of Th1/Th2 CD4+ subsets in leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.239

T cell genetic background determines default T helper phenotype development in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.239

T-cell responses and immunity to experimental infection with leishmania major

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.239

Genetic regulation of macrophage priming/activation: the Lsh gene story

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.239

Immunogenetics in the analysis of resistance to intracellular pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.239

Nature of resistance to leishmaniasis in experimental rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.239

Controlled field trials of a vaccine against New World cutaneous leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.239

Vaccine for prophylaxis and immunotherapy, Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.239

Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.239

Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.239

Salivary gland lysates from the sand fly Lutzomyia longipalpis enhance Leishmania infectivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.239

Subunit vaccination of mice against new world cutaneous leishmaniasis: comparison of three proteins expressed in amastigotes and six adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.239

Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.239

Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.239

Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.239

Vaccination against Leishmania major in a CBA mouse model of infection: role of adjuvants and mechanism of protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.239

Vaccination against cutaneous leishmaniasis: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.239

A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.239

DNA vaccines: a key for inducing long-term cellular immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.239

Potent stimulation of the innate immune system by a Leishmania brasiliensis recombinant protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.239

The Philippine cynomolgus monkey (Macaca fasicularis) provides a new nonhuman primate model of tuberculosis that resembles human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.239

Leishmania major: the suitability of East African nonhuman primates as animal models for cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.239

Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.239

Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.239

Triage by Toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.239

Toll-like receptors: key mediators of microbe detection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.239

An IL-12-based vaccination method for preventing fibrosis induced by schistosome infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.239

Tuberculosis subunit vaccine development: on the role of interferon-γ

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.2.239

21 January 2018

Identifiers

DOI

10.1586/14760584.2.2.239

1 reference

7 August 2017

1 reference

PubMed ID

12899575